Discover how next‑generation small‑molecule GLP‑1 receptor agonists are transforming type 2 diabetes and obesity treatment—offering true oral bioavailability, potential for improved tolerability via biased signaling, and scalable manufacturing for global access.
Discover how orforglipron, a first‑in‑class oral GLP‑1 receptor agonist, delivers injectable‑level weight loss and glycemic control in a once‑daily pill, with phase 2 data in obesity and type 2 diabetes.